Table 2.
PH-Targeted Therapy at Enrollment
| Therapy | Total (N = 750) | Operated (n = 566) | Inoperable (n = 96) | Operable/No Surgery (n = 88) | P Value and Significance |
|---|---|---|---|---|---|
| On any PH therapy | 329 (43.9) | 223 (39.4) | 62 (64.6) | 44 (50) | < .001a,b |
| Parenteral prostanoids | 27 (8.2) | 23 (10.3) | 3 (4.8) | 1 (2.3) | … |
| Inhaled prostanoids | 2 (0.6) | 2 (0.9) | 0 (0) | 0 (0) | … |
| ERA | 31 (9.4) | 21 (9.4) | 5 (8.1) | 5 (11.4) | … |
| PDE-5 inhibitor | 89 (27.0) | 61 (27.4) | 16 (25.8) | 12 (27.3) | … |
| Riociguat | 215 (65.4) | 141 (63.2) | 41 (66.1) | 33 (75) | … |
| Selexipag | 1 (0.3) | 0 (0) | 1 (1.6) | 0 (0) | … |
| Calcium channel blocker | 16 (4.9) | 12 (5.4) | 1 (1.6) | 3 (6.8) | … |
| Chronic inhaled NO | 1 (0.3) | 1 (0.4) | 0 (0) | 0 (0) | … |
| Oral treprostinil | 2 (0.6) | 1 (0.4) | 1 (1.6) | 0 (0) | … |
| > 1 PH-targeted therapy | 51 (15.5) | 36 (16.1) | 5 (8.1) | 10 (22.7) | … |
Data on specific classes of drugs are presented as No. (%). n = total no. of subjects in cohort on pulmonary hypertension (PH)-targeted therapy (% of subjects in cohort on PH-targeted therapy). ERA = endothelin receptor antagonist; NO = nitric oxide; PDE-5 = phosphodiesterase type 5.
a
Comparison among three groups, P < .05 statistically significant.
b
Between-group (Inoperable vs Operated) comparisons, P < .017 statistically significant.